Kiniksa Pharmaceuticals International (KNSA) Stock Overview
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for KNSA from our risk checks.
KNSA Community Fair Values
Create NarrativeSee what 37 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Kiniksa Pharmaceuticals International, plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$48.13 |
| 52 Week High | US$49.33 |
| 52 Week Low | US$18.26 |
| Beta | 0.091 |
| 1 Month Change | 4.63% |
| 3 Month Change | 16.68% |
| 1 Year Change | 120.27% |
| 3 Year Change | 361.02% |
| 5 Year Change | 163.44% |
| Change since IPO | 147.20% |
Recent News & Updates
Recent updates
Kiniksa: Arcalyst Is The Engine, But KPL-387 Is The Accelerator
Jan 24
New IL-1 Receptor Antagonist Trials Will Expand Therapeutic Options
Advancing KPL-387 could drive revenue growth with expanded leadership in the recurrent pericarditis market if successful.Lacklustre Performance Is Driving Kiniksa Pharmaceuticals International, plc's (NASDAQ:KNSA) Low P/S
Apr 23
Big Pipeline Updates From Kiniksa Pharmaceuticals
Feb 25Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain
Feb 13Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story
Oct 07Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 07Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Jul 24Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Shareholder Returns
| KNSA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.0% | 2.3% | -0.3% |
| 1Y | 120.3% | 31.7% | 16.1% |
Return vs Industry: KNSA exceeded the US Biotechs industry which returned 31.7% over the past year.
Return vs Market: KNSA exceeded the US Market which returned 16% over the past year.
Price Volatility
| KNSA volatility | |
|---|---|
| KNSA Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: KNSA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KNSA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 366 | Sanj Patel | www.kiniksa.com |
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
Kiniksa Pharmaceuticals International, plc Fundamentals Summary
| KNSA fundamental statistics | |
|---|---|
| Market cap | US$3.69b |
| Earnings (TTM) | US$59.01m |
| Revenue (TTM) | US$677.56m |
Is KNSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNSA income statement (TTM) | |
|---|---|
| Revenue | US$677.56m |
| Cost of Revenue | US$307.22m |
| Gross Profit | US$370.35m |
| Other Expenses | US$311.34m |
| Earnings | US$59.01m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.77 |
| Gross Margin | 54.66% |
| Net Profit Margin | 8.71% |
| Debt/Equity Ratio | 0% |
How did KNSA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/01 08:07 |
| End of Day Share Price | 2026/04/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kiniksa Pharmaceuticals International, plc is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | BofA Global Research |
| Edward Nash | Canaccord Genuity |
| Geoffrey Meacham | Citigroup Inc |